MADIGAN JOINS $35 MILLION SETTLEMENT WITH PFIZER
Madigan & 41 Attorneys General Reach Settlement Over Illegal Marketing of Kidney Transplant Drug Rapamune
Chicago — Attorney General Lisa Madigan today announced a national $35 million settlement with Pfizer Inc. for illegally marketing a drug designed to prevent kidney transplant rejection for use in non-kidney transplant patients.
Madigan and 41 other states joining the settlement allege the drug’s manufacturer, former Wyeth Pharmaceuticals which was purchased by Pfizer in 2009, illegally marketed Rapamune for uses not approved by the U.S. Food and Drug Administration (FDA). The company allegedly marketed the drug in illegal combinations with other transplant medications and for treating non-kidney transplant patients after surgery. The states also allege Wyeth offered financial incentives to doctors and hospitals to prescribe Rapamune for such unapproved uses.
“Promoting drugs for unapproved uses is a potentially deadly practice that can threaten patients’ lives. The FDA needs to determine that drugs are safe for a specific treatment before they are prescribed,” Madigan said.
The settlement requires Pfizer to ensure that its marketing and promotional practices do not unlawfully promote Rapamune or any Pfizer product. Specifically, Pfizer must not:
Illinois will receive more than $1.3 million under the settlement. Joining Madigan in reaching today’s settlement were attorneys general from the following states: Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Hawaii, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Tennessee, Texas, Utah, Virginia, Washington and Wisconsin.